Decreased cerebral glucose metabolism in patients with brain tumors

An effect of corticosteroids

M. J. Fulham, A. Brunetti, L. Aloj, R. Raman, A. J. Dwyer, G. Di Chiro

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

The authors measured cerebral glucose metabolism (CMR(glu)) using [18F]fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) in patients with brain tumors to evaluate the effect of exogenous corticosteroids (in this instance, dexamethasone) on glucose metabolism. Fifty-six FDG-PET studies obtained in 45 patients with unilateral supratentorial brain tumors were analyzed. Patients with brain tumors were divided into three groups: 1) patients with cushingoid symptoms, who had been treated with combinations of radiotherapy and chemotherapy taking oral dexamethasone; 2) patients not taking dexamethasone but treated with radiotherapy; and 3) patients not taking dexamethasone who had not been treated with radiotherapy. Serial FDG-PET scans were obtained in eight of the cushingoid patterns. Glucose metabolism was measured in the contralateral cerebral and ipsilateral cerebellar hemispheres in patients and compared to measurements taken from 19 normal volunteers. The authors found that in the cushingoid brain tumor patients there was a marked reduction in CMR(glu) compared to normal volunteers and other brain tumor patients (Kruskal-Wallis test; p 0.001). In the majority of patients who had serial FDG-PET scans, there was a decline in glucose metabolism over time and in one patient, in whom dexamethasone was reduced in dosage, there was a subsequent increase in CMR(glu). The authors conclude that there is a generalized reduction in CMR(glu) in brain tumor patients taking dexamethasone compared to other brain tumor patients and normal volunteers, and that this effect is independent of radiotherapy, concurrent anticonvulsant medication, and transhemispheric functional disconnection (transhemispheric diaschisis).

Original languageEnglish
Pages (from-to)657-664
Number of pages8
JournalJournal of Neurosurgery
Volume83
Issue number4
Publication statusPublished - 1995

Fingerprint

Brain Neoplasms
Adrenal Cortex Hormones
Glucose
Dexamethasone
Deoxyglucose
Positron-Emission Tomography
Radiotherapy
Healthy Volunteers
Supratentorial Neoplasms
Combination Drug Therapy
Anticonvulsants

Keywords

  • [F]fluoro-2-deoxyglucose positron emission tomography
  • brain neoplasm
  • corticosteroids
  • glucose metabolism

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Fulham, M. J., Brunetti, A., Aloj, L., Raman, R., Dwyer, A. J., & Di Chiro, G. (1995). Decreased cerebral glucose metabolism in patients with brain tumors: An effect of corticosteroids. Journal of Neurosurgery, 83(4), 657-664.

Decreased cerebral glucose metabolism in patients with brain tumors : An effect of corticosteroids. / Fulham, M. J.; Brunetti, A.; Aloj, L.; Raman, R.; Dwyer, A. J.; Di Chiro, G.

In: Journal of Neurosurgery, Vol. 83, No. 4, 1995, p. 657-664.

Research output: Contribution to journalArticle

Fulham, MJ, Brunetti, A, Aloj, L, Raman, R, Dwyer, AJ & Di Chiro, G 1995, 'Decreased cerebral glucose metabolism in patients with brain tumors: An effect of corticosteroids', Journal of Neurosurgery, vol. 83, no. 4, pp. 657-664.
Fulham, M. J. ; Brunetti, A. ; Aloj, L. ; Raman, R. ; Dwyer, A. J. ; Di Chiro, G. / Decreased cerebral glucose metabolism in patients with brain tumors : An effect of corticosteroids. In: Journal of Neurosurgery. 1995 ; Vol. 83, No. 4. pp. 657-664.
@article{a62ce158a0874664b293ca81a1f455df,
title = "Decreased cerebral glucose metabolism in patients with brain tumors: An effect of corticosteroids",
abstract = "The authors measured cerebral glucose metabolism (CMR(glu)) using [18F]fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) in patients with brain tumors to evaluate the effect of exogenous corticosteroids (in this instance, dexamethasone) on glucose metabolism. Fifty-six FDG-PET studies obtained in 45 patients with unilateral supratentorial brain tumors were analyzed. Patients with brain tumors were divided into three groups: 1) patients with cushingoid symptoms, who had been treated with combinations of radiotherapy and chemotherapy taking oral dexamethasone; 2) patients not taking dexamethasone but treated with radiotherapy; and 3) patients not taking dexamethasone who had not been treated with radiotherapy. Serial FDG-PET scans were obtained in eight of the cushingoid patterns. Glucose metabolism was measured in the contralateral cerebral and ipsilateral cerebellar hemispheres in patients and compared to measurements taken from 19 normal volunteers. The authors found that in the cushingoid brain tumor patients there was a marked reduction in CMR(glu) compared to normal volunteers and other brain tumor patients (Kruskal-Wallis test; p 0.001). In the majority of patients who had serial FDG-PET scans, there was a decline in glucose metabolism over time and in one patient, in whom dexamethasone was reduced in dosage, there was a subsequent increase in CMR(glu). The authors conclude that there is a generalized reduction in CMR(glu) in brain tumor patients taking dexamethasone compared to other brain tumor patients and normal volunteers, and that this effect is independent of radiotherapy, concurrent anticonvulsant medication, and transhemispheric functional disconnection (transhemispheric diaschisis).",
keywords = "[F]fluoro-2-deoxyglucose positron emission tomography, brain neoplasm, corticosteroids, glucose metabolism",
author = "Fulham, {M. J.} and A. Brunetti and L. Aloj and R. Raman and Dwyer, {A. J.} and {Di Chiro}, G.",
year = "1995",
language = "English",
volume = "83",
pages = "657--664",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "4",

}

TY - JOUR

T1 - Decreased cerebral glucose metabolism in patients with brain tumors

T2 - An effect of corticosteroids

AU - Fulham, M. J.

AU - Brunetti, A.

AU - Aloj, L.

AU - Raman, R.

AU - Dwyer, A. J.

AU - Di Chiro, G.

PY - 1995

Y1 - 1995

N2 - The authors measured cerebral glucose metabolism (CMR(glu)) using [18F]fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) in patients with brain tumors to evaluate the effect of exogenous corticosteroids (in this instance, dexamethasone) on glucose metabolism. Fifty-six FDG-PET studies obtained in 45 patients with unilateral supratentorial brain tumors were analyzed. Patients with brain tumors were divided into three groups: 1) patients with cushingoid symptoms, who had been treated with combinations of radiotherapy and chemotherapy taking oral dexamethasone; 2) patients not taking dexamethasone but treated with radiotherapy; and 3) patients not taking dexamethasone who had not been treated with radiotherapy. Serial FDG-PET scans were obtained in eight of the cushingoid patterns. Glucose metabolism was measured in the contralateral cerebral and ipsilateral cerebellar hemispheres in patients and compared to measurements taken from 19 normal volunteers. The authors found that in the cushingoid brain tumor patients there was a marked reduction in CMR(glu) compared to normal volunteers and other brain tumor patients (Kruskal-Wallis test; p 0.001). In the majority of patients who had serial FDG-PET scans, there was a decline in glucose metabolism over time and in one patient, in whom dexamethasone was reduced in dosage, there was a subsequent increase in CMR(glu). The authors conclude that there is a generalized reduction in CMR(glu) in brain tumor patients taking dexamethasone compared to other brain tumor patients and normal volunteers, and that this effect is independent of radiotherapy, concurrent anticonvulsant medication, and transhemispheric functional disconnection (transhemispheric diaschisis).

AB - The authors measured cerebral glucose metabolism (CMR(glu)) using [18F]fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) in patients with brain tumors to evaluate the effect of exogenous corticosteroids (in this instance, dexamethasone) on glucose metabolism. Fifty-six FDG-PET studies obtained in 45 patients with unilateral supratentorial brain tumors were analyzed. Patients with brain tumors were divided into three groups: 1) patients with cushingoid symptoms, who had been treated with combinations of radiotherapy and chemotherapy taking oral dexamethasone; 2) patients not taking dexamethasone but treated with radiotherapy; and 3) patients not taking dexamethasone who had not been treated with radiotherapy. Serial FDG-PET scans were obtained in eight of the cushingoid patterns. Glucose metabolism was measured in the contralateral cerebral and ipsilateral cerebellar hemispheres in patients and compared to measurements taken from 19 normal volunteers. The authors found that in the cushingoid brain tumor patients there was a marked reduction in CMR(glu) compared to normal volunteers and other brain tumor patients (Kruskal-Wallis test; p 0.001). In the majority of patients who had serial FDG-PET scans, there was a decline in glucose metabolism over time and in one patient, in whom dexamethasone was reduced in dosage, there was a subsequent increase in CMR(glu). The authors conclude that there is a generalized reduction in CMR(glu) in brain tumor patients taking dexamethasone compared to other brain tumor patients and normal volunteers, and that this effect is independent of radiotherapy, concurrent anticonvulsant medication, and transhemispheric functional disconnection (transhemispheric diaschisis).

KW - [F]fluoro-2-deoxyglucose positron emission tomography

KW - brain neoplasm

KW - corticosteroids

KW - glucose metabolism

UR - http://www.scopus.com/inward/record.url?scp=0029113635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029113635&partnerID=8YFLogxK

M3 - Article

VL - 83

SP - 657

EP - 664

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 4

ER -